|Bid||17.47 x 1400|
|Ask||17.53 x 800|
|Day's Range||16.97 - 17.98|
|52 Week Range||13.87 - 69.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.00|
RESEARCH TRIANGLE PARK, N.C., April 02, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca,.
RESEARCH TRIANGLE PARK, N.C., March 04, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca,.
Reported positive findings in all four randomized Phase 2 clinical trials of trilaciclib in 2018Clinical program updates to be provided at Investor Day 2019 on March 6Management.
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019.
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
LOS ANGELES, Feb. 20, 2019 -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of G1 Therapeutics, Inc. (NASDAQ: GTHX) investors concerning the.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
G1 THERAPEUTICS (GTHX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.
RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
G1 Therapeutics Inc (NASDAQ: GTHX ) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing ...
Achieved both primary endpoints: statistically significant reductions in the duration and occurrence of Grade 4 neutropeniaClinically meaningful reductions in rates of.
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Patients on trilaciclib received more chemotherapy cycles than those in the control armTrilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L.
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC) have been selected for a poster discussion Spotlight Session presentation on December 5, 2018 at the 2018 San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas. "Metastatic triple-negative breast cancer is difficult to treat.